Delayed US filing for vortioxetine the first under Lundbeck/Takeda alliance
This article was originally published in Scrip
Lundbeck and Takeda have made the first filing under their 2007 alliance for the joint development and commercialisation of Lundbeck pipeline compounds for mood and anxiety disorders, applying for the US approval of vortioxetine (Lu AA21004) for major depressive disorder in adults.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.